Evaluation of efficacy and safety of pregabalin and carbamazepine in reducing pai
Phase 2
- Conditions
- Evaluation of the efficacy and safety of pregabalin and carbamazepine in patients with postherpetic neuralgia.Zoster with other nervous system involvementB02.2
- Registration Number
- IRCT20210725051977N1
- Lead Sponsor
- Islamic Azad University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Age older than 18
History of postherpetic neuralgia for at least 1 month
Exclusion Criteria
History of Allergy to carbamazepine or pregabaline
History of kidney or liver disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of post-herpetic neuralgia in each group. Timepoint: 2, 5 and 8 weeks after starting the treatment. Method of measurement: visual analogue scale.
- Secondary Outcome Measures
Name Time Method Frequency of adverse drug complications in each group. Timepoint: 2, 5 and 8 weeks after starting the drug, or as soon as warning complications occurred. Method of measurement: check list including possible adverse drug reactions following carbamazepine or pregabalin.